Stockholm, Sweden & Turku, Finland – July 11, 2023 – 1stOncology/BioSeeker Group AB, a top 10 global pharma analytic provider, and OncoBone Ltd, a specialist in oncology and bone diseases, jointly announce the publication of “Insights into immuno-oncology drug development landscape with focus on bone metastasis” in the journal Frontiers in Immunology (Impact Factor 7.3).
This peer-reviewed article provides important timely insights to new and emerging immunotherapies with evidence for effects on bone metastases. Bone is among the main sites of metastasis in breast, prostate and other major cancers. However, bone metastases remain incurable causing high mortality, severe skeletal-related effects and decreased quality of life.
In order to provide an insight into the current immuno-oncology drug development landscape, 1stOncology, an award-winning cancer drug development resource, was used to identify 24 novel immunotherapies in preclinical or clinical development for breast and prostate cancer with data available on bone metastasis.
“We have previously performed searches for clinical studies including patients with bone metastases in immunotherapy trials and have concluded that the number of peer-reviewed publications in this area is very low” said Dr. Tiina Kähkönen, Chief Scientific Officer at OncoBone
“… considering the importance of this topic and knowing there are opportunities in development, we turned to an expanded data search using 1stOncology for finding therapies with data available for bone metastasis from more abundant information sources such as news, patents and meeting abstracts that include the latest published data available with a dramatic difference in the number of search results” Dr. Kähkönen added.
This review summarizes data available for the 24 identified novel immunotherapies. The data reveals how bone metastases can be approached using different modalities and the tumor microenvironment in bone provides many potential targets in immune, bone and tumor cells. Three of the identified therapies were considered to be especially promising as their targets are related to tumor growing in bone metastatic microenvironment and their clinical evaluation followed outcomes in bone metastatic patients with relevant outcome measurements.
“Considering that bone metastases are a high unmet medical need, it is surprising how few relevant studies finally address the efficacy of novel therapies on bone metastases either in preclinical or clinical studies” said Dr. Jussi Halleen, Chief Executive Officer at OncoBone.
“We are very pleased to see that 1stOncology could be such a substantial resource to dramatically improve the identification of immuno-oncology drug development related to bone metastasis and so rapidly provide the necessary data for this timely and very up to date publication” said Dr. Ronnie Andersson, Chief Scientific Officer at 1stOncology/BioSeeker Group.
With the recent emergence of osteoimmuno-oncology (OIO), a concept that emphasizes the significance of interactions between tumor, immune and bone cells in promoting tumor growth in bone metastasis, more therapeutic opportunities that primarily target bone metastasis are expected in the future.
The Frontiers in Immunology paper is titled “Insights into immuno-oncology drug development landscape with focus on bone metastasis” and can be accessed here.
About 1stOncology
1stOncology™ is an award-winning, market leading drug intelligence solution driving discovery of new opportunities in cancer drug development. Our mission is to deliver a superior intelligence service to cancer drug stakeholders and to make 1stOncology the go-to solution for those who are serious about their investment in oncology.
For more information about 1stOncology, visit https://www.1stoncology.com/awards
About BioSeeker Group
BioSeeker Group, founded in 1999 with offices in both Europe (Stockholm, Sweden) and the US (Boston, MA), helps stakeholders in cancer drug development and cancer care achieve excellence in drug development and treatment acumen through expert network (KOLs), data integration and technology solutions (artificial intelligence/machine learning) in our award-winning 1stOncology platform. For more information, please visit https://www.bioseeker.com
About OncoBone
OncoBone offers scientific expertise to pharmaceutical and biotech industry and their service providers globally, with key areas of operations in oncology and bone diseases, and bone metastasis as a unique field of expertise. For more information, please visit https://oncobone.com/
For further information please contact: BioSeeker Group AB Tel: +46-8-6731700 E-mail: [email protected] Our Offices: Stockholm, Sweden | Boston, MA USA
Newsletter & Market Alerts – Whitepapers – Awards – Publications – Testimonials – Twitter – LinkedIn |